Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masakazu Fujio

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Bioorganic & Medicinal Chemistry|November 17, 2007
Glycolipids as immunostimulating agentsDouglass Wu, Masakazu Fujio, Chi-Huey Wong
Nuclear Medicine and Biology|April 25, 2006
Synthesis and evaluation of [125I]I-TSA as a brain nicotinic acetylcholine receptor alpha7 subtype imaging agentMikako Ogawa, Ryo Tatsumi, Masakazu Fujio, et al.
Brain Research|March 23, 2011
Neuroprotective effects of a novel water-soluble poly(ADP-ribose) polymerase-1 inhibitor, MP-124, in in vitro and in vivo models of cerebral ischemiaYasuhiro Egi, Shigeru Matsuura, Tomoyuki Maruyama, et al.
Journal of Molecular Biology|September 8, 2009
Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligandsAndré Schiefner, Masakazu Fujio, Douglass Wu, et al.
Nuclear Medicine and Biology|September 18, 2002
Synthesis and evaluation of (11)C-labeled (S)-N-[[1-(2-phenylethyl) pyrrolidin-2-yl]methyl]-3-methylthiobenzamide as a PET 5-HT(1A) receptor ligandMasakazu Fujio, Shinji Nagata, Kazunori Kawamura, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
1,5-Benzodioxepin derivatives as a novel class of muscarinic M3 receptor antagonistsShuji Sonda, Kenichi Katayama, Masakazu Fujio, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2004
(+)-3-[2-(Benzo[b]thiophen-2-yl)-2-oxoethyl]-1-azabicyclo[2.2.2]octane as potent agonists for the alpha7 nicotinic acetylcholine receptorRyo Tatsumi, Kohji Seio, Masakazu Fujio, et al.
Journal of the American Chemical Society|July 13, 2006
Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activityMasakazu Fujio, Douglass Wu, Raquel Garcia-Navarro, et al.
Journal of Medicinal Chemistry|April 2, 2005
Discovery of the alpha7 nicotinic acetylcholine receptor agonists. (R)-3'-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-[1',3']oxazolidin-2'-one as a novel, potent, selective, and orally bioavailable ligandRyo Tatsumi, Masakazu Fujio, Hiroyuki Satoh, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvantXiangming Li, Masakazu Fujio, Masakazu Imamura, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Bioorganic & Medicinal Chemistry|November 17, 2007
Glycolipids as immunostimulating agentsDouglass Wu, Masakazu Fujio, Chi-Huey Wong
Nuclear Medicine and Biology|April 25, 2006
Synthesis and evaluation of [125I]I-TSA as a brain nicotinic acetylcholine receptor alpha7 subtype imaging agentMikako Ogawa, Ryo Tatsumi, Masakazu Fujio, et al.
Brain Research|March 23, 2011
Neuroprotective effects of a novel water-soluble poly(ADP-ribose) polymerase-1 inhibitor, MP-124, in in vitro and in vivo models of cerebral ischemiaYasuhiro Egi, Shigeru Matsuura, Tomoyuki Maruyama, et al.
Journal of Molecular Biology|September 8, 2009
Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligandsAndré Schiefner, Masakazu Fujio, Douglass Wu, et al.
Nuclear Medicine and Biology|September 18, 2002
Synthesis and evaluation of (11)C-labeled (S)-N-[[1-(2-phenylethyl) pyrrolidin-2-yl]methyl]-3-methylthiobenzamide as a PET 5-HT(1A) receptor ligandMasakazu Fujio, Shinji Nagata, Kazunori Kawamura, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
1,5-Benzodioxepin derivatives as a novel class of muscarinic M3 receptor antagonistsShuji Sonda, Kenichi Katayama, Masakazu Fujio, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2004
(+)-3-[2-(Benzo[b]thiophen-2-yl)-2-oxoethyl]-1-azabicyclo[2.2.2]octane as potent agonists for the alpha7 nicotinic acetylcholine receptorRyo Tatsumi, Kohji Seio, Masakazu Fujio, et al.
Journal of the American Chemical Society|July 13, 2006
Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activityMasakazu Fujio, Douglass Wu, Raquel Garcia-Navarro, et al.
Journal of Medicinal Chemistry|April 2, 2005
Discovery of the alpha7 nicotinic acetylcholine receptor agonists. (R)-3'-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-[1',3']oxazolidin-2'-one as a novel, potent, selective, and orally bioavailable ligandRyo Tatsumi, Masakazu Fujio, Hiroyuki Satoh, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvantXiangming Li, Masakazu Fujio, Masakazu Imamura, et al.
Pageof 2